Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN FRANCISCO, May 02, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV)...
-
SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
-
- Favorable safety and tolerability profile- Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies- Selected for inclusion in “Best of ILC” presentation- Company to...
-
Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV cccDNA shown to have a...
-
SAN FRANCISCO, March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
-
SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
-
SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
-
SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
-
First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a...
-
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate ...